Another limitation lies in the fact that most patients (73%) in the present series were treated with ipilimumab monotherapy, which is no longer the standard of care in melanoma; instead, first-line melanoma treatment nowadays involves anti-PD-1 monoclonal antibodies, applied both as single agents and in combination with ipilimumab. This evidence concerns the gene PDCD1 and melanoma.